November 29, 2016 - By Richard Conner
In an analyst note issued on today, finnCap maintained their Corporate rating on Premaitha Health Plc (LON:NIPT)‘s stock. The price target indicates a potential upside of 146.00% from company’s close price.
Out of 2 analysts covering Premaitha Health Plc (LON:NIPT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 24 is the highest target while GBX 20 is the lowest. The GBX 22 average target is 172.28% above today’s (GBX 8.08) stock price. Premaitha Health Plc has been the topic of 28 analyst reports since September 22, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained it with “Buy” rating and GBX 24 target price in Tuesday, March 29 report. Panmure Gordon maintained Premaitha Health PLC (LON:NIPT) rating on Wednesday, December 2. Panmure Gordon has “Buy” rating and GBX 24 price target. On Tuesday, March 29 the stock rating was maintained by FinnCap with “Corporate”. FinnCap maintained it with “Corporate” rating and GBX 20 target price in Monday, July 4 report. FinnCap maintained the stock with “Corporate” rating in Monday, March 21 report. FinnCap maintained Premaitha Health PLC (LON:NIPT) rating on Monday, October 31. FinnCap has “Corporate” rating and GBX 20 price target. The firm has “Corporate” rating by FinnCap given on Monday, November 21. The rating was maintained by Panmure Gordon on Tuesday, September 22 with “Buy”. The stock of Premaitha Health PLC (LON:NIPT) has “Buy” rating given on Monday, October 12 by Panmure Gordon. The stock of Premaitha Health PLC (LON:NIPT) has “Buy” rating given on Monday, March 21 by Panmure Gordon.
About 205,970 shares traded hands. Premaitha Health PLC (LON:NIPT) has declined 14.29% since April 29, 2016 and is downtrending. It has underperformed by 19.55% the S&P500.
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The company has a market cap of 18.66 million GBP. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. It currently has negative earnings. The IONA test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases.
More news for Premaitha Health PLC (LON:NIPT) were recently published by: Businesswire.com, which released: “Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo …” on December 14, 2015. Uk.Finance.Yahoo.com‘s article titled: “Premaitha Health PLC (NIPT.L)” and published on July 07, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.